Dana Taylor

What have patients alleged here?

And you wrote about a smaller number of lawsuits linked to even more serious conditions.

Tell me about some of those.

As you said, some of these patients shared their stories with USA Today.

Before we get into more of those, how have Novo Nordisk and Eli Lilly, the drug makers who manufacture these drugs, responded on the issue of the safety of GLP-1s?

I want to turn now to some of the plaintiffs, starting with 63-year-old Todd Engel of Maryland.

Why was he taking Ozempic and what severe injury did he allege happened due to his use of a GLP-1 drug?

And how has the manufacturer, Novo Nordisk, responded to the case?

Jo Helen McLean, a 72-year-old real estate agent from Oklahoma City, began taking Wegovy in 2023.

What did she share with USA Today?

And I know that you asked Novo Nordisk for a comment on her case.

How did they respond?

Austin, how widespread is the use of GLP-1s and how many plaintiffs have allegedly suffered severe outcomes from using these drugs?

You and your colleagues reviewed a random sample of 100 of the thousands of federal lawsuits filed.

What else can you share with us about these plaintiffs?

Austin, there's no denying what's alleged in some of these cases is alarming.

There are stories that you've told that I'll never forget.

But what did experts you spoke with point to you as the positive outcomes linked to GLP-1 use?

I know many go beyond weight loss.

What hurdles are the plaintiffs facing here?